Press Releases

Contacts:
Lance Longwell 
IMS Communications
(610) 834-5338           
llongwell@us.imshealth.com 

Jeff Forringer
IntrinsiQ Research
(732) 447-2024
jforringer@intrinsiq.com

Complete Patient View of Oncology Care Available In Seven Major Markets

PLYMOUTH MEETING, PA, AND WALTHAM, MA, August 2, 2006 – IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, and IntrinsiQ Research, the premier provider of U.S. oncology information, today announced a multi-year alliance to support the industry’s growing need for comprehensive, global insights into cancer treatments. Through the alliance, IMS gains an exclusive license to incorporate IntrinsiQ’s U.S.-based anonymized patient-level oncology information into IMS’s multi-country oncology offering—providing a complete view of cancer care into seven major markets worldwide. The integration of this information, together with IMS’s advanced analytics and global consulting capabilities, will provide the evidential database — and expertise — to help pharmaceutical and biotech clients make more informed decisions in this rapidly expanding, increasingly competitive space.

“Oncology is the second largest and fastest-growing therapy class in the world — one where patient treatment is highly complex and variable,” said Gilles Pajot, executive vice president, IMS Health. “Our clients, including those in the biotech market, have a compelling need to better understand the various dimensions of clinicians’ decisions for a line of therapy at various stages of cancer. This alliance between IMS and IntrinsiQ will lead to new offerings and expanded consulting insights that will both guide and drive our clients’ key commercial decisions in oncology, locally and globally.”

The integration of IntrinsiQ data with IMS Oncology Analyzer™, an offering that provides an evidence-based view of the oncology market, creates one of the largest commercially available oncology repositories of its kind for cancer treatment insights. IMS’s oncology market intelligence and consulting capabilities now span the U.S., Japan, Germany, France, U.K., Italy, and Spain.

The combination of IntrinsiQ’s oncology data with other IMS core information assets, which include anonymized patient level data as well as global sales and prescription insights, also will lead to expanded product and consulting capabilities that support client needs across the entire oncology product lifecycle — from licensing and forecasting, to pricing and reimbursement, to health economics and health outcomes, to promotion and sales.

IntrinsiQ’s oncology database, which will augment IMS’s global offerings with clinically rich information captured at the point of care, features data on 80 tumor types and more than 13,000 unique, anonymized patient records updated monthly. U.S. data collected through IntelliDose™, IntrinsiQ’s clinical dosing software, includes real-world, anonymized patient information from community-based clinics and hospitals, private practices, and academic and military facilities. It contains more than five million administrations of drug therapy and 36 months of history available for in-depth analysis.

“We have been working with the oncology community for more than a decade and have an extensive understanding of the U.S. cancer market because we capture significant detail around patient treatment at the point of care,” said Brent Clough, CEO and president, IntrinsiQ Research. “By partnering with IMS, we are working with an industry leader to leverage our shared relationships and offerings within a truly global framework. Together, our capabilities offer pharmaceutical and biotech clients a level of oncology intelligence that’s unmatched.”

Said Pajot, “This alliance is another step in IMS’s strategy to broaden our oncology information assets and fuel consulting expertise to help our clients meet the challenges of this key market. This includes continuing to build our substantial expertise in health economics and outcomes research in 2006, particularly as it relates to oncology, to support pharma’s need for proving the value of medicines.”

About IMS
Operating in more than 100 countries, IMS Health is the world's leading provider of market intelligence to the pharmaceutical and healthcare industries. With $1.8 billion in 2005 revenue and more than 50 years of industry experience, IMS offers leading-edge business intelligence products and services that are integral to clients' day-to-day operations, including portfolio optimization capabilities; launch and brand management solutions; sales force effectiveness innovations; managed care and over-the-counter offerings; and consulting and services solutions that improve ROI and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com.

About IntrinsiQ
IntrinsiQ Research is the premier provider for U.S. oncology information and analysis. IntrinsiQ’s market leading software application, IntelliDose™ captures the treatment decisions and details of over 13,000 patients a month—creating an unrivalled database of accurate, detailed and timely information about the oncology care process. This database is the foundation for products and services designed to uniquely address the business issues and decisions made by pharmaceutical product managers, market researchers and financial analysts. Additional information is available at http://www.intrinsiq.com.

Forward-Looking Statements
This press release includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Although IMS Health believes the expectations contained in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.  This information may involve risks and uncertainties that could cause actual results of IMS Health to differ materially from the forward-looking statements.  Factors that  could cause or contribute to such differences include, but are not limited to (i) the risks associated with operating on a global basis, including fluctuations in the value of foreign currencies relative to the U.S. dollar, and the ability to successfully hedge such risks, (ii) to the extent IMS Health seeks growth through acquisitions and joint ventures, the ability to identify, consummate and integrate acquisitions and joint ventures on satisfactory terms, (iii) the ability to develop new or advanced technologies and systems for its businesses on time and on a cost-effective basis, (iv) regulatory, legislative and enforcement initiatives, particularly in the areas of medical privacy and tax, (v) to the extent unforeseen cash needs arise, the ability to obtain financing on favorable terms, and (vi) deterioration in economic conditions, particularly in the pharmaceutical, healthcare or other industries in which IMS Health’s customers operate.